Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition - Precision MRI: Advanced Quantitative Imaging and Biomarkers for Brain Tumors

Precision MRI: Advanced Quantitative Imaging and Biomarkers for Brain Tumors

Oral

Neuro B

Monday, 11 May 2026

Ballroom East

13:50 - 15:40

Moderators: Yoshiyuki Watanabe & Katherine Reinshagen

Session Number: 304-03

No CME/CE Credit

Similar Sessions

This session explores advanced MRI and quantitative imaging approaches to characterize brain tumors, focusing on glioblastoma, brain metastases, and diffuse midline glioma. Topics include diffusion- and perfusion-based tumor habitat imaging, MR elastography for treatment response, vessel architecture imaging, and time-dependent diffusion MRI. The session also covers tractography-based invasion indices, MR spectroscopy biomarkers, and IVIM-based methods to refine diagnosis, stratify risk, and guide personalized therapy.

Skill Level: Intermediate

13:50		304-03-001. How to integrate advanced quantitative MR imaging for brain tumors Yoshiyuki Watanabe Shiga University of Medical Science, Shiga, Japan
14:01		304-03-002. Vessel Architecture Imaging enables Quantitative Differentiation of Glioblastoma and Brain Metastasis Dongnan Zhao, Wanxin Dong, Jin Fang, ke zhang, Shiji Li, Jingfei Li, Guihua Jiang, Chen Chen, Ye Li, Zhanli Hu, Xin Liu, Dong Liang, Hairong Zheng, Na Zhang Paul C. Lauterbur Research Center for Biomedical Imaging, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China Impact: VAI enables quantitative characterization of tumor microvasclatuure beyond convenional perfusion MRI. Combining VSI and CBV from both tumor core and peritumoral edema provides a noninvasive, highly accurate imaging tool for clinical differentiation between GBM and SBM, facilitating personalized neuro-oncologic management.
14:12		304-03-003. Integrative MRI-Transcriptomics Reveal a Distinct Morphomolecular Identity of Brain Metastases Divergent from Gliomas Neha Yadav, Vivek Tiwari Indian Institute of Science Education and Research (IISER) Berhampur, Odisha, India Impact: By integrating MRI-derived tumor geometry with transcriptomic profiling, this study demonstrates that brain metastases, though originating from diverse primary cancers, acquire a unified morphomolecular state distinct from gliomas. This integrative-framework enables non-invasive discrimination and reveals metastatic adaptation to the brain-microenvironment.
14:23		304-03-004. Differentiating glioblastoma from solitary brain metastasis using diffusion imaging–based simple, interpretable tumor habitat Guohua Zhao, Mengyang He, Xingyu Liu, Xiaoyue Ma, Eryuan Gao, Jing Yan, Yufei Gao, MENGZHU WANG, Yang Gao, Yong Zhang The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China Impact: NODDI-based, simple and interpretable tumor habitat features effectively distinguish glioblastoma from solitary brain metastasis, enabling models with performance comparable to radiomics or deep learning while being more practical for clinical implementation.
14:34		304-03-005. Preliminary findings in differentiating pseudoprogression from true progression in high-grade gliomas using MR Elastography Bin Deng, Maya Viera, W. Scott Hoge, Ralph Sinkus, Elizabeth Gerstner, Samuel Patz Harvard Medical School, Boston, United States of America Impact: Once its added value has been demonstrated, MRE can be combined with other MRI techniques already used in routine care to enable timely and tailored clinical interventions in patients with high-grade gliomas, especially glioblastomas, to improve patient outcomes.
14:45		304-03-006. Time-Dependent Diffusion MRI: Unveiling Microstructural Characteristics for Distinguishing Glioblastoma and Brain Metastases Shuqi Qiao, Lin-Feng Yan, Yi Zhu Tangdu Hospital, Fourth Military Medical University, Xi'an, China Impact: Time-dependent diffusion MRI (TDD-MRI) derived parameters enable accurate and noninvasive differentiation between glioblastoma (GBM) and brain metastases (BM), effectively bridging the diagnostic gap of conventional imaging and providing a robust theoretical basis to support clinicians in treatment decision-making.
14:56		304-03-007. Assessing the Value of CBV in Identifying Early Recurrence Risk in Glioblastoma Mahsa Servati, Ziyu Fu, Aliya Anil, Chinmay Mokashi, Nazanin Majd, Vinaykumar Puduvalli, C. Chad Quarles The University of Texas MD Anderson Cancer Center, Houston, United States of America Impact: Quantifying the fraction of high-CBV regions within glioblastoma may provide an early, practical imaging-based estimate of risk of recurrence, addressing a key unmet challenge in anticipating tumor regrowth and guiding timely clinical intervention.
15:07		304-03-008. Extremely elevated total creatine and myo-inositol are indicators of molecular glioblastoma Francesca Ravera, Capucine Cadin, Alberto Picca, Bertrand Mathon, Matteo Bendini, Stéphane Lehéricy, Mehdi Touat, Franck Bielle, Marc Sanson, Malgorzata Marjanska, Lucia Nichelli, Francesca Branzoli Paris Brain Institute - ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne University, Paris, France Impact: Extremely high total creatine and myo-inositol, together with low tNAA, are indicators of molecular glioblastoma. This novel ¹H-MRS marker could help clinicians identify molecular GBMs earlier, which are often misunderstood as low-grade, thereby better guiding diagnosis and treatment.
15:18		304-03-009. Cystathionine Quantification by proton MRS for Preoperative Adult-Type Diffuse Gliomas Kazufumi Kikuchi, Koji Yamashita, Daichi Momosaka, Masaoki Kusunoki, Osamu Togao, Kousei Ishigami Kyushu University, Fukuoka, Japan Impact: Cystathionine quantification via ¹H-MRS may serve as a supportive metabolic biomarker for identifying oligodendrogliomas preoperatively. Integrated with imaging and clinical data, it holds potential to improve molecular subtype prediction and guide surgical planning in diffuse gliomas.